NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Aug 13, 2026TL;DR. NeuroOne reported Q3 FY2026 product revenue of $2.0M (up 16% YoY) with record 59.9% gross margins and $2.7M in new orders, received ISO 13485 certification enabling international expansion, but guided FY2026 recognized revenue to $9.2M–$10.5M versus $11.2M in orders due to supplier/manufacturing constraints, while net loss widened to $2.0M and cash fell to $2.0M.
- + Product gross margins expanded to a record 59.9% from 53.9% on favorable mix
- + New product orders grew 43% YoY to $2.7M, outpacing recognized revenue and building backlog
- + Received ISO 13485 certification ahead of schedule, enabling international commercialization with Zimmer Biomet
- − FY2026 recognized revenue guided to $9.2M–$10.5M versus $11.2M in orders due to supplier/manufacturing constraints
- − Net loss widened to $2.0M ($0.23/share basic) from $1.5M ($0.19/share) YoY
- − Cash and equivalents declined to $2.0M at June 30, 2026 from $6.6M at September 30, 2025
- − Company raising capital through dilutive ATM offerings ($0.4M in Q3 plus $1.0M post-quarter)
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| open purchase orders | $5.4M | as of September 30, 2026 | — |
| backlog | $1.7M | Q3 FY2026 | — |
| product gross margin | 59.9% | Q3 FY2026 | — |
| product orders | $2.7M | Q3 FY2026 | — |
| product orders for fiscal year 2026 | $11.2M | FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NMTC
this stock
NEUROONE MEDICAL TECHNOLOGIES Corp
|
$12.11M | — | +163.5% | — | 0.8% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.7% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.8% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NMTC | +3.7% | -33.1% | -74.6% | +9.7% | -75.2% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | +1.7% | -34.9% | -85.9% | +7.6% | -89.4% |